This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
NovoCure (NVCR) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
NovoCure (NVCR) delivered earnings and revenue surprises of 76.47% and 1.25%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
NovoCure (NVCR) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
NovoCure (NVCR) delivered earnings and revenue surprises of -150% and 1.14%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate NovoCure (NVCR) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
NovoCure (NVCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Charles River Laboratories (CRL) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Charles River (CRL) delivered earnings and revenue surprises of 2.89% and 1.52%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Avantor, Inc. (AVTR) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Avantor, Inc. (AVTR) delivered earnings and revenue surprises of 9.09% and 0.19%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
NovoCure (NVCR) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
NovoCure (NVCR) delivered earnings and revenue surprises of -116.67% and -6.42%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate NovoCure (NVCR) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
NovoCure (NVCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Accuray (ARAY), C-RAD Ink Deal to Enhance Breast Cancer Treatment
by Zacks Equity Research
Accuray's (ARAY) latest agreement is likely to improve breast cancer treatment.
NovoCure (NVCR) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
NovoCure (NVCR) delivered earnings and revenue surprises of -800.00% and -5.64%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
NovoCure (NVCR) Q2 Earnings Preview: What's in the Cards?
by Zacks Equity Research
NovoCure (NVCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Oncology Space Gains Momentum in 2021: 5 Stocks to Focus on
by Debanjana Dey
Oncology stocks like OncoCyte (OCX), PerkinElmer (PKI), Catalent (CTLT), Cardiff Oncology (CRDF) and NovoCure (NVCR) are expected to continue their run over the next few months.
Zacks.com featured highlights include: Manchester United, NovoCure, Palantir Technologies and JD.com
by Zacks Equity Research
Zacks.com featured highlights include: Manchester United, NovoCure, Palantir Technologies and JD.com
4 Toxic Stocks That May Disrupt Your Peace & Portfolio
by Rimmi Singhi
Investors who can pinpoint the overhyped toxic stocks and discard them at the right time are the ones who are poised to benefit.
Why NovoCure (NVCR) Might Surprise This Earnings Season
by Zacks Equity Research
NovoCure (NVCR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
NovoCure (NVCR) is Overbought: Is A Drop Coming?
by Zacks Equity Research
NovoCure Limited (NVCR) has moved higher as of late, but there could definitely be trouble on the horizon for this company.
Analysts Estimate NovoCure (NVCR) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
NovoCure (NVCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Company News for Apr 14, 2021
by Zacks Equity Research
Companies in the news are: MFNC, NVCR, RIGL, VTVT
NovoCure (NVCR) Moves 49.6% Higher: Will This Strength Last?
by Zacks Equity Research
NovoCure (NVCR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
NovoCure (NVCR) Q4 Earnings and Revenues Miss Estimates
by Zacks Equity Research
NovoCure (NVCR) delivered earnings and revenue surprises of -69.23% and -0.01%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Why Earnings Season Could Be Great for NovoCure (NVCR)
by Zacks Equity Research
NovoCure (NVCR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
NovoCure (NVCR) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
NovoCure (NVCR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Are Options Traders Betting on a Big Move in NovoCure (NVCR) Stock?
by Zacks Equity Research
Investors need to pay close attention to NovoCure (NVCR) stock based on the movements in the options market lately.
Healthcare Stock Q3 Earnings Due on Oct 29: NVCR, CRL & More
by Zacks Equity Research
Coronavirus is going to affect the earnings results of healthcare players. While hospitals and health insurers might have suffered the COVID-19 impact, others providing virtual care and COVID-19-related services are likely to have gained from the same.
Kroger, Hyatt Hotels, ResMed, LHC Group and NovoCure highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Kroger, Hyatt Hotels, ResMed, LHC Group and NovoCure highlighted as Zacks Bull and Bear of the Day
3 Large-Cap MedTech Growth Stocks to Buy Amid the Pandemic
by Sriparna Ghosal
Let's take a look at three large-cap MedTech stocks that are currently flourishing on the back of a number of positive developments.